[A23-135] Lanadelumab (hereditary angioedema, 2 to < 12 years) – Benefit assessment according to §35a Social Code Book V
Last updated 15.03.2024
Project no.:
A23-135
Commission:
Commission awarded on 14.12.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Children aged 2 to 11 years for routine prevention of recurrent attacks of hereditary angioedema
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A23-135_en
| Project no. | Title | Status |
|---|---|---|
| A21-63 | Lanadelumab (hereditary angioedema) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| G19-04 | Lanadelumab - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |